证券代码：832566 证券简称：梓橦宫 公告编号：2024-029 四川梓橦宫药业股份有限公司 2023 年度独立董事述职报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 2023 年度，本人作为四川梓橦宫药业股份有限公司（以下简称"公司"）的 独立董事，在任职期间严格按照《公司法》《证券法》《北京证券交易所股票上市 规则（试行）》《北京证券交易所上市公司持续监管指引第 1 号——独立董事》 等法律法规、规范性文件及公司《公司章程》《独立董事工作制度》等相关规定， 勤勉尽责，积极出席各项会议，认真审议各项提案并提出建议，始终维护全体股 东尤其是中小股东的利益，切实履行了独立董事的责任与义务。现就 2023 年度 履职情况报告如下： 一、出席董事会、股东大会会议的情况 2023 年度，公司共召开了 8 次董事会，7 次股东大会，本人通过现场或网络 方式按时出席会议，没有委托他人出席会议或缺席的情形。认真履行相关审批程 序，独立、客观、审慎地发表意见并行使表决权，对审议的议案均无异议，也无 弃权、反对 ...

关于四川梓幢宫药业股份有限公司 非经营性资金占用及其他关联资金往来情况的专项审核说明 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 www.zhcpa.cn 录 目 中汇会专[2024]3219号 四川梓權宫药业股份有限公司全体股东: 我们接受委托,审计了四川梓幢宫药业股份有限公司(以下简称梓植宫公 司)2023年度财务报表,并出具了中汇会审[2024]3218号无保留意见的审计报告, 在此基础上对后附的梓樟宫公司管理层编制的《2023年度非经营性资金占用及其他 关联资金往来情况汇总表》(以下简称汇总表)进行了审核。 | 一、非经营性资金占用及其他关联资金往来情况的专项 | 页 次 | | --- | --- | | 审核说明 | 1-2 | 二、非经营性资金占用及其他关联资金往来情况汇总表 3 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、 ...

证券代码：832566 证券简称：梓橦宫 公告编号：2024-025 四川梓橦宫药业股份有限公司 第四届监事会第三次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 5.会议主持人：监事会主席蒋晓风 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开、议案审议程序符合《公司法》等有关法律、行政法 规和《公司章程》的相关规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《2023 年度监事会工作报告》 1.议案内容： 根据法律法规和《公司章程》的规定，由公司监事会主席汇报监事会 2023 年度工作情况。 1.会议召开时间：2024 年 4 月 2 日 2.会议召开地点：公司会议室 3.会议召开方式：现场 4.发出监事会会议通知的时间和方式：2024 年 3 月 22 日以书面方式发出 2.议案表决结果：同意 3 票；反对 0 票；弃权 0 票。 2.议案表决结果：同意 3 票； ...

平安证券股份有限公司 关于四川梓橦宫药业股份有限公司 2023 年度募集资金存放和使用情况的专项核查报告 平安证券股份有限公司(以下简称平安证券或保荐机构)作为四川梓橦宫药 业股份有限公司(以下简称梓橦宫或公司)向不特定合格投资者公开发行股票并 在北京证券交易所上市的保荐机构和持续督导机构，对梓橦宫履行持续督导义务。 根据《证券发行上市保荐业务管理办法》《北京证券交易所上市公司持续监管办 法（试行）》《北京证券交易所上市公司持续监管指引第 9 号——募集资金管理》 《北京证券交易所证券发行上市保荐业务管理细则》等有关规定，平安证券及其 指定保荐代表人对梓橦宫 2023 年度（以下简称"本年度"）募集资金存放与使用 情况进行了专项核查，具体情况如下: 一、募集资金基本情况 （一）募集资金金额、资金到位时间 经中国证券监督管理委员会《关于核准四川梓橦宫药业股份有限公司向不特 定合格投资者公开发行股票的批复》（证监许可[2021] 2369 号）核准， 同意公 司向不特定合格投资者公开发行人民币普通股股票 19,000,000 股（含行使超额 配售选择权），每股面值 1.00 元。本次初始发行 16,521,740 ...

四川梓橦宫药业股份有限公司 2023 年度董事会财务与审计委员会履职情况报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 四川梓橦宫药业股份有限公司（以下简称"公司"）第三届董事会财务与审 计委员会根据《公司法》《证券法》《上市公司独立董事管理办法》《北京证券交 易所股票上市规则（试行）》和《公司章程》《董事会财务与审计委员会工作细则》 等相关法律法规及公司规章制度的规定和要求，在 2023 年度积极开展工作、勤 勉尽责。现将履职情况汇报如下： 一、 基本情况 公司第三届董事会财务与审计委员会由 3 名董事组成，分别为黄元林、程志 鹏、李云，其中黄元林、程志鹏为独立董事，主任委员（召集人）由会计专业人 士黄元林担任。 根据《上市公司独立董事管理办法》《北京证券交易所股票上市规则（试行）》 《北京证券交易所上市公司持续监管指引第 1 号——独立董事》等相关规定，公 司于 2023 年 12 月 28 日召开 2023 年第六次临时股东大会完成第四届董事会换 届选举。第四届董事会由 7 名董事组成，其中 ...

Financial Performance - The company's operating revenue for 2023 was approximately ¥408.05 million, a decrease of 7.71% compared to ¥442.16 million in 2022[27]. - The net profit attributable to shareholders for 2023 was approximately ¥102.32 million, showing a slight increase of 0.25% from ¥102.07 million in 2022[27]. - The net profit after deducting non-recurring gains and losses was approximately ¥88.28 million, representing a growth of 12.09% compared to ¥78.76 million in 2022[27]. - The gross profit margin for 2023 was 80.94%, an increase from 79.96% in 2022[27]. - The basic earnings per share for 2023 was ¥0.71, a 1.43% increase from ¥0.70 in 2022[27]. - The company maintained a weighted average return on equity of 14.15% for 2023, down from 15.19% in 2022[27]. - Total assets increased by 4.28% to CNY 878.20 billion from CNY 842.18 billion in 2022[29]. - Total liabilities decreased by 2.09% to CNY 127.60 billion from CNY 130.32 billion in 2022[29]. - Operating cash flow increased by 7.56% to CNY 115.77 million from CNY 107.63 million in 2022[29]. - The company reported a revenue of CNY 408.05 million for 2023, unchanged from the preliminary report[31]. - The company achieved operating revenue of ¥408,049,692.89, a decrease of 7.71% compared to the same period last year[42]. - Net profit attributable to shareholders increased by 0.25% to ¥102,324,161.07, while net profit excluding non-recurring gains and losses grew by 12.09% to ¥88,279,575.36[42]. - The company’s total revenue for 2023 was approximately CNY 408 million, a decrease of 7.71% compared to CNY 442 million in 2022[56]. - The gross profit margin improved to 80.94% in 2023 from 79.96% in 2022[56]. - The net profit for 2023 was CNY 102.24 million, reflecting a slight increase of 0.63% from CNY 101.60 million in 2022[56]. Market Strategy and Development - The company plans to focus on expanding its market presence and enhancing its product development capabilities in the upcoming year[10]. - The company is actively pursuing new product development and technological advancements to strengthen its competitive position in the pharmaceutical industry[10]. - The company is actively expanding its OTC channel and enhancing its online sales system to build an efficient national marketing network[43]. - The company is committed to expanding its product pipeline and improving its pain relief product line through ongoing R&D efforts[43]. - The company plans to enhance its product pipeline and accelerate the launch of new products to maintain steady growth[51]. - The company aims to build a high-quality traditional Chinese medicine service system by 2025, enhancing its capabilities in disease prevention and treatment[50]. - The company is strategically positioning itself in the healthcare sector through investments in mental health and wellness-related businesses[79]. - The company plans to focus on product innovation and market expansion, with a strategic emphasis on digital marketing and e-commerce to drive sales growth[110]. - The company is committed to improving production management capabilities through smart upgrades and lean production practices, aiming to enhance quality and reduce costs[110]. - The company will expand its traditional Chinese medicine supply chain by increasing the scale and quality of herbal medicine cultivation[110]. Research and Development - The company holds 26 invention patents and 99 drug production approvals, focusing on CNS and digestive system drugs[38]. - The company has initiated 3 new R&D projects and holds a total of 84 patent certificates, including 26 invention patents[43]. - The company has five main R&D projects, including original Chinese medicine varieties, classic prescriptions, chemical generics, consistency evaluation of major varieties, and secondary development of exclusive traditional Chinese medicine products[199]. - The R&D team consists of over 50 personnel, including 1 PhD and 5 Master's degree holders, with 44.90% holding professional technical titles[199]. - The company employs a project-based collaborative R&D model, partnering with domestic universities and research institutions to enhance its research capabilities[199]. - The company has initiated three new drug R&D projects at the end of the reporting period, laying the groundwork for its development during the 15th Five-Year Plan[200]. - The company has developed a patented production process for its products, improving stability and reducing production costs[196]. - The company emphasizes the importance of intellectual property protection, focusing on the creation, registration, and safeguarding of patents, trademarks, and trade secrets[196]. Environmental and Social Responsibility - The company has implemented strict environmental protection measures, including wastewater treatment and air quality management, achieving compliance with national standards[102]. - The company has established an emergency response mechanism for environmental pollution incidents, ensuring timely reporting and control of potential hazards[103]. - The company has received recognition for its employee welfare initiatives, including the "Model Workers' Home" award in Sichuan Province[97]. - The company maintains a focus on sustainable development, balancing economic benefits with social and environmental responsibilities[98]. - The company has successfully renewed its pollution discharge permits, demonstrating ongoing compliance with environmental regulations[100]. - The company actively responds to the national "Rural Revitalization" strategy by establishing a traditional Chinese medicine planting experimental base, contributing to local employment and income increase[96]. Corporate Governance and Management - The company has engaged Zhonghui Certified Public Accountants for its audit, receiving a standard unqualified opinion on its financial statements[10]. - The company has established a robust internal control system for revenue recognition to mitigate risks associated with improper revenue reporting[92]. - The company has engaged Zhonghui CPA as its external auditor for the 2023 annual audit, ensuring compliance with auditing standards[94]. - The company has implemented a stock incentive plan, granting 2.4 million restricted shares at a price of 3.21 yuan per share to 36 individuals[129]. - The company has repurchased 3 million shares using its own funds for the stock incentive plan, with a maximum repurchase price set at 9.00 yuan per share[130]. - The company has a total of 7 directors, 3 supervisors, and 4 senior management personnel[161]. - The company’s management remuneration is determined based on operational scale and industry salary levels[165]. - The company has focused on talent acquisition through various recruitment channels, including university graduates and social recruitment[171]. - The company conducted diverse training activities to improve employee professional skills, laying a solid foundation for future development[171]. Compliance and Risk Management - The company emphasizes compliance and risk management, aiming to establish a long-term risk prevention mechanism to protect investor interests[111]. - The company has implemented measures to control the quality of traditional Chinese medicinal materials from the source, including the establishment of a planting base[114]. - The company has not experienced any significant changes in major risks during the reporting period[115]. - The company has not faced any major litigation or arbitration matters during the reporting period[119]. Shareholder and Investor Relations - The company emphasizes investor relations management through various communication channels, ensuring transparency and engagement with small and medium investors[98]. - The company’s profit distribution proposal requires approval from the board and shareholders, ensuring transparency and consideration of minority shareholders' opinions[151]. - The company has maintained strict compliance with its fundraising management regulations, ensuring no misuse of funds by major shareholders or actual controllers[146]. - The company has not made any adjustments to its profit distribution policy during the reporting period[152]. Product Development and Sales - The company has launched a new product, Pregabalin Oral Solution, and is actively expanding its marketing network nationwide[66]. - The revenue from the main product, Sodium Cytidine, decreased by 11.71% year-on-year, particularly in the South and Central regions, where the decline reached 30%[66]. - The company reported a decrease in gross profit margin in the South region by 3.85 percentage points, while the Northwest region saw an increase of 6.10 percentage points[65]. - The company is focusing on expanding its OTC channel and enhancing its online sales system to improve market reach[190]. - The sales model primarily involves academic promotion and distribution through third-party agencies, ensuring compliance with industry regulations[191]. - The company has seen a 27.70% increase in revenue from other products, indicating successful diversification of its product offerings[190].

公司本次以自有闲置资金购买理财产品的金额为人民币 2,000.00 万元， 截止目前，公司使用自有闲置资金购买理财产品的未到期余额为 21,894.00 万 元，占公司 2022 年度经审计净资产的 30.93%，达到上述披露标准，现予以披 露。 证券代码：832566 证券简称：梓橦宫 公告编号：2024-023 四川梓橦宫药业股份有限公司 关于使用自有闲置资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 授权委托理财情况 （一）购买理财产品的审议情况 四川梓橦宫药业股份有限公司（以下简称"公司"）于 2023 年 9 月 28 日 召开第三届董事会第二十三次会议及 2023 年 10 月 20 日召开 2023 年第五次临 时股东大会，审议通过了《关于使用自有闲置资金购买理财产品的议案》。为 提高公司资金的使用效率，增加投资收益，在不影响公司主营业务的正常发展， 并确保公司正常经营需求的前提下，公司拟使用不超过人民币 35,000.00 万元 （含 35,000.00 ...

证券代码：832566 证券简称：梓橦宫 公告编号：2024-024 四川梓橦宫药业股份有限公司 关于使用部分闲置募集资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 授权委托理财情况 （一）购买理财产品的审议情况 四川梓橦宫药业股份有限公司（以下简称"公司"）于 2023 年 8 月 22 日 召开第三届董事会第二十二次会议、第三届监事会第二十次会议，审议通过了 《关于使用部分闲置募集资金购买理财产品的议案》，为提高资金使用效率， 在确保资金安全、不影响募投项目资金使用的前提下，公司拟使用不超过人民 币 14,000.00 万元的闲置募集资金购买理财产品，自公司董事会审议通过之日 起 12 个月内有效。具体内容详见公司 2023 年 8 月 23 日在北京证券交易所披 露平台（www.bse.cn）披露的《关于使用部分闲置募集资金购买理财产品的公 告》（公告编号：2023-088）。 （二）购买理财产品的披露标准 根据《北京证券交易所股票上市规则（试行）》相关规定，交易 ...

证券代码：832566 证券简称：梓橦宫 公告编号：2024-022 四川梓橦宫药业股份有限公司 关于马甲子胶囊获得开展 Ia 期临床试验伦理许可的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 马甲子胶囊取得阶段性成果情况 在研产品名称：马甲子胶囊 主要研究者：徐建明 伦理委员会对该试验/研究的审查结果：同意 二、 对公司的影响 （一） 对公司财务状况和经营成果的影响 公司及子公司将严格按照国家相关要求组织开展临床试验。由于药物研发的 特殊性，一类新药研发周期较长，公司及子公司将按计划分阶段投入研发，短期 对公司业绩不会产生明显影响。 三、 风险提示 近日，四川梓橦宫药业股份有限公司（以下简称"公司"）全资子公司成都 马甲子生物科技有限公司（以下简称"子公司"）获得中国人民解放军总医院医 学伦理委员会审查签发的药物临床试验伦理意见函（伦审第 C2023-039-01 号）， 主要信息如下： 项目名称：评价马甲子胶囊在晚期实体瘤患者中的完全性、耐受性、药代动 力学及初步有效性的 Ia 期剂量 ...

证券代码：832566 证券简称：梓橦宫 公告编号：2024-021 四川梓橦宫药业股份有限公司 关于使用部分闲置募集资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 授权委托理财情况 （一）购买理财产品的审议情况 四川梓橦宫药业股份有限公司（以下简称"公司"）于 2023 年 8 月 22 日 召开第三届董事会第二十二次会议、第三届监事会第二十次会议，审议通过了 （二）购买理财产品的披露标准 根据《北京证券交易所股票上市规则（试行）》相关规定，交易的成交金额 占上市公司最近一期经审计净资产的 10%以上且超过 1,000 万元的应当予以披 露；上市公司连续 12 个月滚动发生委托理财的，以该期间最高余额为成交额， 适用上述标准。 公司本次以闲置募集资金购买理财产品的金额为人民币 3,600.00 万元， 截止目前，公司使用闲置募集资金购买理财产品的未到期余额为 8,688.00 万 元，占公司 2022 年度经审计净资产的 12.27%，达到上述披露标准，现予以披 露。 ...